Navigation Links
Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
Date:8/4/2010

MORRISTOWN, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI) today announced that Sigurdur Oli Olafsson has joined the Company as Executive Vice President, Global Generics, effective September 1, 2010.  In this position, Mr. Olafsson will have responsibility for global generic sales and marketing, with an emphasis on leading the expansion of Watson's position in global markets.  Mr. Olafsson most recently served as Chief Executive Officer of the Actavis Group.  He succeeds Thomas R. Russillo who will retire at the end of 2010.  Mr. Olafsson will report to Paul Bisaro, President and Chief Executive Officer of Watson, and he will be headquartered in Morristown, NJ. Mr. Olafsson and Mr. Russillo will work closely during the three-month transition period.

"We are delighted to have an executive with Sigurdur's global experience join our team as we move from the integration of the Arrow Group to the next phase of maximizing our current commercial footprint and capitalizing on additional opportunities to expand into new markets," said Paul Bisaro, Watson's President and Chief Executive Officer.  "Tom has done an exceptional job during the integration phase, and we thank him for his efforts.  We look forward to Sigurdur's expertise in helping us shape strategies that will build on the foundation Tom and his team have established, as well as helping us to identify strategies and opportunities that will enable Watson to leap-frog to the next level of global competition."

Mr. Olafsson most recently served as CEO of Actavis Group, where he was responsible for overseeing Actavis' $2.4 billion global pharmaceutical business with operations in more than 40 countries.  From 2006 to 2008, Mr. Olafsson served as Deputy CEO of Actavis Group, and was CEO, Actavis Inc. US and Chief Executive Corporate Development from 2003-2006, where he led Actavis US sales and marketing organization, and also led the acquisition and integration of Pharma Avalanche, Biovena, Lotus Laboratories, Amide Pharmaceuticals and Alpharma Generics.  

Prior to joining Actavis, Mr. Olafsson held increasingly responsible positions with Pfizer's Global Research and Development organization in both the U.S. and in the U.K. from 1998 until 2003.  Prior to joining Pfizer, he served as head of Drug Development for Omega Farma in Iceland for four years.  

Mr. Olafsson has an M.S. in Pharmacy (Cand Pharm) from the University of Iceland, Reykjavik, and is a published author.

Mr. Russillo was named Executive Vice President, Global Generics, in 2009 and led the restructuring of Watson's global generics business following the completion of the acquisition of the Arrow Group in December 2009.   Mr. Russillo had served as Executive Vice President and President of the Generic Division since 2006. Prior to joining Watson, he served as a consultant to the Company in connection with the Company's integration planning related to the acquisition of Andrx. From January 2005 until September 1, 2006, Mr. Russillo served as a consultant to various clients in the pharmaceutical industry. From 1990 through 2004, he was President of Ben Venue Laboratories, a division of Boehringer Ingelheim, which included Bedford Laboratories and Roxanne Laboratories. Prior to Ben Venue, he held a number of senior positions with Baxter International.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others,  such risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Promotes Robert Stewart to Executive Vice President, Global Operations
2. Watson Confirms Renvela® for Oral Suspension Patent Challenge
3. Watson to Host Conference Call and Webcast to Discuss Second Quarter 2010 Earnings
4. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
5. Watsons Generic Prograf® 5 mg Receives FDA Approval
6. Watson Launches Generic Exelon®
7. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
8. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
9. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
10. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
11. Watson Launches Generic Version of LIPITOR® in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Finally, a bruise cream that really ... cream can be incorporated into the post-surgical treatment plans of a variety of other ... dermaka cream is very effective for bruising and causes a rapid resolution of bruising ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan and University ... Lamar location as of July 13, 2016. , Dr. Daulat earned her Doctorate of ... she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical ...
(Date:6/23/2016)... ... 23, 2016 , ... SyncDog, Inc. , the leading ... is featured in the current issue of Silicon Review magazine. Silicon ... technology solutions and features them in their magazine. The magazine allows top-level executives ...
(Date:6/23/2016)... ... 23, 2016 , ... The U.S. Supreme Court decision on immigration has significant ... The Senior Citizens League (TSCL) . “President Obama’s executive actions on immigration would ... who worked in this country illegally, even though the newly - issued green cards ...
Breaking Medicine News(10 mins):